bluebird bio
CAMBRIDGE, MA · CIK 0001293971 · Biotech · Acquired
Lentiviral gene therapies for blood disorders and neurological diseases
bluebirdbio.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $179M
- 4 Form D · Sep 2021
- 60 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 24 granted · 16 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2009201120132015201720192021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $29,412,661 | |
| Private capital raised | Form D · SEC | $15,000,000 | |
| Private capital raised | Form D · SEC | $60,000,000 | |
| Private capital raised | Form D · SEC | $74,977,264 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2277 | Perfect Day, Inc. | — | $222M |
| 2278 | Dren Bio, Inc. | — | $93M |
| 2279 | CURAVAC, INC. | — | $4.7M |
| 2280 | bluebird bio | — | $179M |
| 2281 | EFFECTORBIO, INC. | — | — |
| 2282 | Ensysce Biosciences, Inc. | — | $103M |
| 2283 | VIACYTE, INC. | — | $150M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- John AgwunobiDirector
- Chip BairdExecutive Officer
- Jason ColeExecutive Officer
- Wendy DixonDirector
- James GeraghtyDirector
- Steven GillisDirector
- Ramy IbrahimDirector
- Nick LeschlyDirector · Executive Officer
- Daniel LynchDirector
- John MaraganoreDirector
- Geert-Jan MulderDirector
- Axel PolackDirector
- William SellersDirector
- Robert TepperDirector
- Denice TorresDirector
- Mark VachonDirector
- Jeffrey WalshExecutive Officer
Patents
- Sickled Beta Globin Antibodiesapplication
- Sickled Beta Globin Antibodiesgranted
- Vcn Enhancer Compositions And Methods Of Using The Samegranted
- Compounds For Improved Viral Transductiongranted
- Sickled Beta Globin Antibodiesgranted
- Gene Therapy For Mucopolysaccharidosis, Type Iapplication
- Gene Therapy Of Neuronal Ceroid Lipofuscinosesapplication
- Beta-thalassemia Potency Assayapplication
- Sickle Cell Potency Assayapplication
- Vcn Enhancer Compositions And Methods Of Using The Samegranted
- Bcma Chimeric Antigen Receptorsgranted
- Cblb Endonuclease Variants, Compositions, And Methods Of Usegranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.